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Abstract
Background: Transthyretin (TTR), a traditional biomarker for nutritional and inflammatory status exists in
different molecular variants of yet unknown importance. A truncated form of TTR has recently been described
to be part of a set of biomarkers for the diagnosis of ovarian cancer. The main aim of the study was therefore to
characterize differences in microheterogeneity between ascitic fluid and plasma of women affected with ovarian
cancer and to evaluate the tumor site as the possible source of TTR.
Methods:  Subjects were 48 women with primary invasive epithelial ovarian cancer or recurrent ovarian
carcinoma. The control group consisted of 20 postmenopausal women. TTR and retinol-binding protein (RBP)
levels were measured by enzyme-linked immunoassay (ELISA) and C-reactive protein (CRP) levels by a high-
sensitivity latex particle turbidimetric assay. The molecular heterogeneity of TTR was analysed using
immunoprecipitation and matrix-associated laser desorption ionization time-of-flight mass spectrometry (MALDI-
TOF-MS). Presence of TTR in tumor tissue was determined with indirect peroxidase immunostaining.
Results: TTR and RBP (µg/ml) levels in serum were 148.5 ± 96.7 and 22.5 ± 14.8 in affected women compared
to 363.3 ± 105.5 and 55.8 ± 9.3 in healthy postmenopausal women (p < 0.01). In ascitic fluid, levels were 1.02 ±
0.24 and 4.63 ± 1.57 µg/ml, respectively. The mean levels of TTR and RBP in serum showed a tendency to
decrease with the severity of the disease and were lower in affected women whose CRP levels were > 40 mg/ml
(p = 0.08 for TTR; p < 0.05 for RBP). No differences in TTR microheterogeneity were observed between TTR
isolated from serum of affected and healthy women or from ascitic fluid. TTR occurred rather consistently in four
variants. Mass signals were at 13758 ± 7, 13876 ± 13 (greatest intensity), 13924 ± 21 and 14062 ± 24 Da,
representing native, S-cysteinylated, S-cysteinglycinylated and glutathionylated TTR, respectively. Serum of healthy
and affected women as well as ascitic fluid contained the truncated fragment of TTR (12828 ± 11 Da). No
immunoreactive TTR was observed in the tumor sites.
Conclusion: The severity of the cancer associated catabolism as well as the inflammation status affect serum
TTR and RBP levels. Neither TTR nor its truncated form originates from tumor tissue and its occurrence in
ascites may well reflect the filtration from blood into ascitic fluid.
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Background
TTR, formerly called prealbumin, belongs to a group of
proteins including thyroxine-binding globulin and albu-
min which bind to and transport thyroid hormones in the
blood. TTR is also involved in the metabolism of vitamin
A as it binds RBP, the specific plasma transport protein for
retinol. First identified in 1942 by Kabat et al. [1] in serum
and cerebrospinal fluid, TTR has been described as a so-
called visceral protein that is synthesized in the liver in
response to nutritional supply. TTR plasma levels can thus
be used as a sensitive biochemical parameter of subclini-
cal malnutrition, because both the synthesis of proteins as
well as energy intake are reflected in its serum levels.
Serum levels of TTR, however, are also affected by acute
and chronic diseases associated with an acute-phase
response. Under these conditions, liver activity is con-
verted to the synthesis of acute-phase response proteins,
resulting in a drop in visceral proteins despite adequate
nutritional supply [2-5].
Epithelial ovarian cancer is the leading cause of death
from gynaecologic malignancies in western countries [6].
Most patients are first diagnosed at an advanced stage with
diffuse peritoneal metastasis outside the pelvis (FIGO
stage III or IV). Tumor stage is one of the most important
prognostic factors in ovarian cancer [7]. The 5-year sur-
vival rate for FIGO stage III ranges from 25 to 45%, whilst
for patients diagnosed at FIGO stage I or II survival rates
are between 85 and 95% [8]. Therefore, various strategies
have been investigated to increase the detection rate of
early ovarian cancer. A systematic review by Fung and co-
workers [9] on the screening of postmenopausal women
for ovarian cancer showed that for every 10,000 women
participating in an annual screening program with cancer
associated antigen 125 (CA125) over 3 years, 800 have
had an ultrasound scan due to an elevated CA125, 30
underwent surgery because of an abnormal ultrasound,
whilst only 6 women were diagnosed with ovarian cancer
of whom only three where detected at an early stage.
Therefore, despite the combination of CA125 monitoring
and ultrasound this strategy remains insufficient as a
screening tool.
Unfortunately, most other biomarkers also have low sen-
sitivity and specificity and little predictive value [10].
Application of new technologies for detection of ovarian
cancer could have an important effect on public health
[11], but to achieve this goal, specific and sensitive molec-
ular markers are essential [12,13]. This need is especially
urgent in women, who have a high risk of ovarian cancer
due to family or personal history of cancer, and for
women with a genetic predisposition to cancer due to
abnormalities in predisposition genes [14]. Besides pro-
tein profiling, the determination of changes in the micro-
heterogeneity of a variety of proteins has been suggested
as an approach to biomarker discovery [15].
In plasma, the non-glycosylated TTR is present as a
tetramer of non-covalently bound monomers of ~14 kDa.
Physiologically its importance is related to the transport
of thyroid hormones and retinol. The association of TTR
and RBP is a prerequisite for the homeostatic control of
plasma and retinol levels. In addition to mutations on
protein level, TTR exists in different isoforms [16,17]. The
isoforms results when the cyteine residue on position 10
(Cys10) makes a mixed disulfide with the amino acid
cysteine the peptide cysteinyl-glycine, or the peptide glu-
tathione. The possible importance of this as a risk factor
for the onset of senile systemic amyloidosis remains to be
elucidated [18,19]. Additionally, Cys10  adducts of S-
homocysteine of TTR have been detected in plasma of
humans with hyper-homocysteinemia [20]. Recently, a
new truncated variant of TTR together with apolipopro-
tein A1 and a cleaved fragment of inter-α-trypsin inhibitor
heavy chain H4 were described as an efficient set of new
biomarkers for ovarian cancer in women [21].
In human primary hepatic cancer, the mRNA of TTR,
which is normally highly expressed in the liver, is strik-
ingly suppressed [22]. Not only in hepatic cancer, but also
for broncho-pulmonary carcinoid cancers, TTR was con-
cluded to be a useful marker [23]. Nothing however is
known with regard to ovarian cancer as a source of TTR
itself or cleavage products thereof. Since we have recently
shown that TTR is present in ascitic fluid [24], it cannot be
excluded that its presence might not only arise from an
increased permeability for blood constituents into ascitic
fluid due to an intensified vascularization [25], but may
also reflect the secretion of products synthesized by the
malignant ovary cells due to the intimate contact between
tumor site and ascitic fluid.
The study was thus conducted to primarily characterize
possible differences in microheterogeneity of TTR arising
from posttranslational modifications and/or products of
protein degradation or proteolysis between serum and
ascitic fluid of women with ovarian cancer and also to
evaluate the affected ovary as a possible site of TTR
expression.
Methods
Subjects
The study was conducted on 48 patients (average age 53 ±
11.9; mean ± SD) with ovarian cancer admitted to the
Department of Gynecology and Obstetrics, Charité, Cam-
pus Virchow-Klinikum, Berlin, Germany. All patients
underwent primary surgery with median laparotomy, hys-
terectomy, adenectomy, omentectomy and pelvic and
paraortal lymphadenectomy to achieve maximal tumorBMC Cancer 2005, 5:133 http://www.biomedcentral.com/1471-2407/5/133
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reduction. According to the classifications of the Interna-
tional Federation of Gynecology and Obstetrics (FIGO),
the treated group consisted of four patients with stage Ic,
two with stage IIc, 28 with stage III and 14 with stage IV.
Of the 48 women, 25 were suffering from primary ovarian
carcinoma and 23 had recurrent ovarian carcinoma. The
controls were 20 healthy postmenopausal women (aver-
age age 58 ± 1.0; mean ± SD). The postmenopausal status
was proved by the assessment of LH and FSH. The study
protocol was approved by the hospitals and University of
Potsdam Ethics Committee. All samples and relevant clin-
ical data were obtained from the Tumor Bank Ovarian
Cancer (TOC). Informed consent was obtained from each
participant.
Ascitic fluid was collected under sterile conditions from
the patients with ovarian carcinoma and centrifuged at
1500 × g for 20 min at 4°C. The supernatants were stored
at -80°C. Serum was separated from freshly drawn blood
at the same time of paracentesis and stored at -80°C until
assayed.
Tissue samples were fixed in 4% PBS-buffered paraformal-
dehyde for 24 h and embedded in paraplast. Each of the
samples was stained routinely with haematoxylin and
eosin (H+E) and diagnosed. All tumor samples were
reviewed by a pathologist.
Determination of TTR, RBP and CRP levels
Levels of TTR and RBP in serum and ascitic fluid were
determined by ELISA using polyclonal rabbit anti-human
antibodies (DakoCytomation, Hamburg, Germany) [17].
CRP levels in serum were measured with a high sensitivity
latex turbimetric immunoassay using a latex-coupled
monoclonal mouse anti-human antibody (Olympus AU
600, Biomed, Germany). The sensitivity of this assay was
0.005 mg/dl. The 90th percentile of normal CRP distribu-
tion was 0.3 mg/dl.
Immunoprecipitation of TTR and subsequent analysis by 
MALDI-TOF-MS
TTR from serum and ascitic fluid of 20 randomized repre-
sentative women was prepared by immunoprecipitation.
The subgroup consisted of two patients with FIGO stage Ic
or IIc, 13 with stage III and 5 with stage IV. Briefly, 15 µl
of serum or ascitic fluid was treated with an equal amount
of a polyclonal rabbit anti human antibody (DakoCyto-
mation). The mixture was incubated for two hours at
37°C and then centrifuged at 15.000 × g for 15 min at
room temperature. The supernatant was removed and the
immunoprecipitated complex of TTR and antibody was
then washed with high performance liquid chromatogra-
phy grade water.
To determine the disulfide linkage of TTR adducts, the
immunoprecipitated TTR was treated with dithiothreitol
(DTT). DTT solution, 100 mM in buffer (100 mM
NH4CO3, pH 8.8) was added to the solution at a ratio of
1:1 (DTT solution volume/TTR solution volume). The
mixture was incubated for 2 h at room temperature and
precipitated samples were subsequently subjected to
MALDI-TOF-MS.
MALDI mass spectra of the precipitated TTR from serum
and ascitic fluid were obtained using a Reflex II MALDI-
TOF mass spectrometer (Bruker-Daltonik, Bremen, Ger-
many). MALDI-TOF MS of serum samples was performed
in linear mode at 20 k acceleration voltage using sinapic
acid as matrix. For ionization, a nitrogen laser (337 nm, 3
ns pulse width, 3 Hz) was used. The samples were pre-
pared in a two step procedure: First, 0.5 µl serum were
deposited on the target. Secondly, 0.5 µl saturated
sinapinic acid solution was placed on serum drop and
dried. This step was repeated. The matrix solution con-
tained 1 mg sinapinic acid and equal amounts (25 µl) 1%
trifluoroacetic acid and acetonitrile. For optimisation of
the mass spectra, the laser was aimed either at the central
area of the sample or at the outmost edge of the crystal
rim. All spectra were measured using external calibration.
Immunohistochemistry of TTR
For indirect peroxidase immunostaining of TTR, slides
were deparaffinized, rehydrated in a decreased series of
alcohol to water and exposed for 60 min in 0.5% hydro-
gen peroxide in methanol in order to deactivate endog-
enous peroxidases. Non-specific antibody binding was
blocked for 30 min in Tris-buffered saline (TBS, pH 7.6)
containing 5% bovine serum albumin (BSA; Sigma,
Taufkirchen, Germany). The primary human anti-TTR
antibody (DakoCytomation) was diluted 1:100 in 1%
bovine serum albumin (BSA) in TBS. After overnight incu-
bations at 4°C, the sections were treated with peroxidase-
coupled swine anti-rabbit IgG (DakoCytomation) diluted
1:100 in 1% BSA in TBS for 30 min. The antigen-antibody
binding sites were visualized by incubating the sections in
a solution of diaminobenzidine tetrahydrochloride (DAB;
Sigma) containing 0.01% hydrogen peroxide in 0.1 M
imidazole buffer (pH 7.1). Counterstaining was per-
formed with Papanicolaou hematoxylin. Negative con-
trols, which included the omission of the primary
antibodies, revealed no significant labelling. A positive
control (liver) was included in each individual staining
process. The sections were examined and photographed
with an Olympus BX-50 microscope equipped with a
ColorView 12 CCD video camera (SIS, Münster, Ger-
many). Images were processed using analySIS™ 3.0 soft-
ware (SIS).BMC Cancer 2005, 5:133 http://www.biomedcentral.com/1471-2407/5/133
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Statistical procedures
Values are expressed as means and standard deviations
(SD). Unpaired t tests were performed to compare serum
values with ascitic fluid or to compare between the groups
using standard methods software (SPSS package, version
10.0). P < 0.05 was regarded as statistically significant.
Results
TTR and RBP levels in serum and ascitic fluid
Results of serum and ascitic fluid levels of TTR and RBP are
shown in Table 1. In women with cancer, serum levels of
both TTR and RBP were lower compared to healthy con-
trols (p < 0.01). In the more severe stages of ovarian can-
cer the levels showed a tendency to be even lower. Within
the cancer group, increased levels of CRP (cut-off > 40 mg/
ml) in serum were associated with lower levels of TTR (p
= 0.08) and RBP (p < 0.05) (Fig. 1). TTR and RBP levels in
ascitic fluid were substantially lower compared to serum
(p < 0.01). No obvious differences of TTR and RBP con-
centration in ascitic fluid between FIGO stages were
observed.
TTR microheterogeneity in serum and ascitic fluid
Using the combination of immunoprecipitation and sub-
sequent MALDI-TOF-MS we were able to show that no
obvious differences exists in the microheterogeneity of
TTR between serum of affected and healthy women as well
as in ascitic fluid. TTR monomer occurred rather consist-
ently in four major variants in the range where TTR and its
conjugated forms should normally appear (m/z 13,700 –
14,100). The results are summarized in Table 2. In the
mass spectra of serum and ascitic fluid (Fig. 2 and Tab. 2)
peaks dominated at m/z 13,875.8 ± 12.8 and 13,876.9 ±
13.3 respectively. Three additional mass spectra were
recorded. The mass differences between these variants
were similar in serum and ascitic fluid (Tab. 2). The
molecular mass of 13,757.7 ± 7.1 Da corresponded to the
native, unmodified TTR. The other peaks in serum repre-
senting Cys10 adducts for S-cysteine (TTR- Cys10-S-S-Cys,
mass = 13,875.8 ± 12.8 Da), S-cysteinylglycine (TTR-
Cys10-S-S-CysGly, mass = 13,923.6 ± 21.0) and S-glutath-
ione (TTR- Cys10-S-S-SG, mass = 14,062.1 ± 24.7). The
shift in the mass spectrum of TTR after treatment with
DTT, towards the native form of TTR, indicates that the
adducts are formed via the disulfide linkage at Cys10 (Fig.
2). Additionally, in serum and ascitic fluid a smaller mass
signal could be observed with varying intensity at a molec-
ular mass of 12828 ± 11 Da.
Immunohistochemistry of TTR
In order to assess the expression of TTR within ovarian
cancer tissue we performed immunohistochemical stain-
Table 1: Comparison of levels (mean ± SD) of TTR and RBP in serum and asciticfluid in relation to FIGO-stages and levels of CRP in 
ovarian cancer patients
serum (µg/mL) ascitic fluid (µg/mL) percentage of serum in 
ascitic fluid
TTR RBP TTR RBP TTR RBP
Healthy control n  =  2 0 3 6 3 . 3  ±  1 0 5 . 5 5 5 . 8  ±  9 . 3 ----
All Stages ovarian cancer 148.5 ± 96.7 22.5 ± 14.8 1.022 ± 0.239 4.632 ± 1.572 1.0 ± 0.6 26.2 ± 14.9
Stage I/II ovarian cancer 162.5 ± 69.4 34.2 ± 22.3 0.966 ± 0.375 3.580 ± 0.849 0.8 ± 0.6 14.5 ± 9.8
Stage III ovarian cancer 155.6 ± 107.6 19.5 ± 7.5 1.074 ± 0.185 4.800 ± 1.711 1.0 ± 0.6 27.2 ± 11.8
Stage IV ovarian cancer 129.0 ± 96.0 17.4 ± 7.3 0.965 ± 0.241 4.627 ± 1.672 1.2 ± 0.7 32.1 ± 23.3
Ovarian cancer CRP > 40 mg/l 116.0 ± 94.3 14.2 ± 4.3 1.047 ± 0.213 4.736 ± 1.886 1.4 ± 0.7 35.4 ± 17.2
Ovarian cancer CRP < 40 mg/l 166.3 ± 92.1 24.1 ± 12.5 1.005 ± 0.260 4.503 ± 1.415 0.8 ± 0.5 22.3 ± 11.1
All values for ascitic fluid (if available) are significantly different (p < 0.01) from serum value.
Table 2: Molecular mass of immunoprecipitated TTR (Da, mean ± SD) assigned to different forms1 of TTR between serum and ascitic 
fluid of 20 representative women with ovarian cancer. Values in brackets represent mass differences of modified TTR in relationship to 
the native form of TTR (Da, mean ± SD).
TTR cysTTR cysglycTTR glutTTR
serum 13757.7 ± 7.1 13875.8 ± 12.8 (118.1 ± 13.7) 13923.6 ± 21.0 (166.8 ± 20.9) 14062.1 ± 24.7 (306.4 ± 23.9)
ascitic fluid 13752.7 ± 16.5 13876.9 ± 13.3 (124.2 ± 13.7) 13926.8 ± 11.1 (176.8 ± 1.8) 14042.5 ± 27.0 (294.6 ± 22.7)
1 TTR = native TTR; cysTTR = TTR + cysteinylation; cysglycTTR = TTR + cysteinylglycine; glutTTR = TTR + glutathione; no significant differences between 
molecular masses of serum and ascitic fluid could be observedBMC Cancer 2005, 5:133 http://www.biomedcentral.com/1471-2407/5/133
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ing using a polyclonal TTR antibody in paraffin embed-
ded sections. TTR immunoreactivity was previously tested
in human liver sections and revealed cytoplasmic staining
within hepatocytes (data not shown). In ovarian cancer
tissues diffuse TTR immunostaining was only observed
within blood vessels, haemorrhages or plasma insuda-
tions (Fig. 3). No TTR labelling however was seen within
the epithelial cells of any cancer specimen.
Discussion
Epithelial ovarian cancer is the leading cause of death
from gynaecologic malignancies in western countries
[26,27]. The tumor stage at time of diagnosis and the post-
operative residual tumor mass are important prognostic
factors and are unequivocally related to overall survival
[26]. Other prognostic factors are identified mostly in
small series and are the source of controversial discussion
in the relevant literature.
Serum TTR is traditionally a valid marker for nutritional
status in general and in cancer patients it has gained con-
siderable interest with regard to the use as an early diag-
nostic marker in ovarian cancer [21]. As depletion of
nutritional reserves and a subsequent significant weight
loss can lead to an increased risk of morbidity, reduced
chemotherapy response, and shorter survival in patients
with cancer, TTR is a valid prognostic marker [28]. Inter-
estingly however, TTR and RBP levels of serum are affected
not only by the nutritional status of the individual but are
also reduced during the acute phase response associated
with inflammation [29]. Additionally to quantitative
aspects, the TTR molecule in serum exists in numerous
variants due either to genetic differences or because of
modification on one readily accessible cystein within the
molecule. The microheterogeneity is affected by different
metabolic aspects such as oxidative stress or homocystein
levels [20,30]. Nothing is known however with regard to
possible variation due to metabolic alterations in cancer.
The results of the present study confirm previous results
for cancer patients in general and especially for patients
with ovarian cancer, regarding the greatly reduced serum
levels of TTR and RBP [31]. Interestingly however, the
intensity of the disease has no significant influence on
serum levels, indicating that it is a general phenomenon
possibly associated with cancer induced cachexia which is
already present at early stages. For drawing a general con-
clusion, this group (stage I/II) was too small in sample
size. On the other hand, when the differing inflammatory
statuses were considered, obvious differences were
observed between the cancer patients for serum levels of
TTR and RBP. Using 40 mg/l as cut-off for C-reactive pro-
tein (CRP) TTR and RBP serum levels were reduced in
those individuals with increased CRP values. This clearly
supports observations showing that the inflammation sta-
tus greatly reduces TTR and RBP serum levels as a
consequence of a reduced synthesis of this negative acute-
phase protein in the liver [5].
Using immunological procedures we were recently able to
show the presence of TTR in ascitic fluid from women
with ovarian cancer, however no quantitative data, espe-
cially with regard to cancer stages, is as yet available [32].
In accordance to our previous semi-quantitative study,
TTR in ascitic fluid was more than 100-fold lower when
compared to its serum levels. This ratio is much lower in
comparison to the one observed for RBP (Tab. 1). Based
on the difference between their molecular masses, 55 kDa
Correlation between levels of CRP and TTR in serum (p = 0.08) and between levels of CRP and RBP in ascitic fluid (p < 0.05) Figure 1
Correlation between levels of CRP and TTR in serum (p = 0.08) and between levels of CRP and RBP in ascitic fluid (p < 0.05).BMC Cancer 2005, 5:133 http://www.biomedcentral.com/1471-2407/5/133
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for the hetero-tetramer TTR and 21 kDa for RBP, one
would expect a different ascites/serum ratio, as an inverse
correlation exists between ascites/serum ratio and the
mean of the molecular weight of various proteins [5].
From this observation one could assume that RBP and
TTR are not transferred individually but rather as the com-
plex usually present in serum [33]. In general, results sup-
port the hypothesis that the concentration of TTR and RBP
in ascitic fluid is the result of a passive transfer from serum
into the ascitic fluid. The accumulation of these and other
serum constituents is mainly attributed to the increased
capillary permeability caused by an increase in
permeability-inducing factors such as the vascular
endothelial growth factor (VEGF) [25].
These observations and the fact that no obvious differ-
ences in microheterogeneity between TTR from serum and
ascitic fluid can be observed, both with regard to the
known modification at the Cys10  and the recently
described truncated form, it can be assumed that all TTR
in ascitic fluid originates through a passive transfer from
serum. This is further supported by the observation that
the tumor site itself does not express any immunoreactive
TTR. It can not be excluded however, that the tumor site
or components in the ascitic fluid may have proteolytic
Mass spectra resulting from MALDI-TOF-MS after immunoprecipitation of TTR in plasma (A) and ascites (B) obtained from  women with ovarian cancer Figure 2
Mass spectra resulting from MALDI-TOF-MS after immunoprecipitation of TTR in plasma (A) and ascites (B) obtained from 
women with ovarian cancer. The untreated TTR (I) and the TTR after treatment with dithioretiol (II) are shown.BMC Cancer 2005, 5:133 http://www.biomedcentral.com/1471-2407/5/133
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properties that possibly result in the unobserved modifi-
cations of TTR or other proteins.
With regard to the microheterogeneity of TTR in serum
and ascitic fluid, the results support and confirm previous
studies undertaken by us and others with regard to molec-
ular variants of TTR in serum [17,34-36]. As in these stud-
ies, TTR in serum and ascitic fluid was dominant in four
variants. The 118 Da larger variant is the S-cysteinylated
form of the native TTR whilst the signal at 14,062 Da can
be attributed to the S-glutathionylated TTR form
[30,34,37]. As TTR contains only one cysteine residue
(Cys10), the adduct must result when the Cys10 residue
forms a mixed disulfide with the amino acid cysteine, the
dipeptide cysteinylglycine or the tripeptid glutathione.
The shift in the mass spectrum of TTR variants towards the
native TTR molecule mass in serum and ascites fluid after
treatment with DTT indicates that the adducts are formed
via the disulfide linkage at Cys10. In addition to this, we
confirmed in serum of healthy and affected women as
well as in ascitic fluid the presence of a smaller immuno-
reactive form of TTR with a molecular mass of 12,830 Da,
which was recently identified as a truncated form of TTR
lacking the NH2-terminal 10 amino acids [21]. Its pres-
Histological sections from ovarian malignoma subjected to staining with H+E (A-C) or immunodetection of TTR (D-E) Figure 3
Histological sections from ovarian malignoma subjected to staining with H+E (A-C) or immunodetection of TTR (D-E). Diffuse 
TTR immunostaining was only detectable within blood vessels (arrows) or plasma insudations (asterisks) (D). No immunoreac-
tivity was observed within epithelial cells of any tumour specimen (D-F)). Negative controls, which included the omission of the 
primary antibody, revealed no significant labelling (G-I).BMC Cancer 2005, 5:133 http://www.biomedcentral.com/1471-2407/5/133
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ence in both serum and ascitic fluid supports once again
the idea of passive transfer from serum into ascitic fluid
during its accumulation.
Conclusion
Results show that, although the microheterogeneity of
TTR itself and the occurrence of possible immunoreactive
fragments thereof in serum and ascites fluid is unaffected
by the cancer. Absolute levels of TTR as well as RBP in
serum are negatively affected by the disease and by
inflammatory processes associated with the cancer. It can-
not be excluded that other metabolic effects yet to be
defined might interact with the cancerous process. Thus,
to fully validate the specificity of TTR or any of its frag-
ments as a biomarker for ovarian cancer, a careful
selection of controls has to be implemented, including
consideration of nutritional status and the presence of
inflammatory processes especially the possible influence
of various hepatic diseases.
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